Loading...
•
Jun 30, 2023
Mersana Q2 2023 Earnings Report
Mersana reported financial results for the second quarter ended June 30, 2023.
Key Takeaways
Mersana Therapeutics announced its Q2 2023 financial results, highlighting the advancement of XMT-1660 and XMT-2056, along with progress in its Dolasynthen and Immunosynthen platforms. The company is focused on developing new product candidates and business development opportunities. Mersana is working to address the clinical hold on its Phase 1 clinical trial of XMT-2056.
Advanced XMT-1660 and Dolasynthen Platform with the plan to complete the dose escalation portion of its Phase 1 clinical trial in 2023 and initiate the dose expansion portion of the trial in 2024.
Advanced XMT-2056 and Immunosynthen Platform and is working diligently to address the clinical hold on its Phase 1 clinical trial of XMT-2056.
Supported Janssen Biotech under a collaboration and license agreement that focuses on discovering novel Dolasynthen ADCs for up to three targets.
Supported Merck KGaA, Darmstadt, Germany under a collaboration and license agreement that focuses on discovering novel Immunosynthen ADCs for up to two targets.
Forward Guidance
This press release contains “forward-looking” statements and information within the meaning of the Private Securities Litigation Reform Act of 1995.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...